103499-15-6

Basic information

• Product Name: N-HYDROXY-NONANAMIDINE
• Synonyms: N-Hydroxynonanimidamide;Nonanamide oxime
• CAS NO: 103499-15-6
• Molecular Formula: C₉H₂₀N₂O
• Molecular Weight: 172.27
• Mol File: 103499-15-6.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-HYDROXY-NONANAMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-HYDROXY-NONANAMIDINE(103499-15-6)
• EPA Substance Registry System: N-HYDROXY-NONANAMIDINE(103499-15-6)

Safety Data

• Hazardous Substances Data: 103499-15-6(Hazardous Substances Data)

Upstream product

• 111-83-1 1-bromo-octane 
• 2243-27-8 nonanonitrile 

Downstream Products

• 1332498-56-2 5-[2-(3,4-dimethoxy-phenyl)-vinyl]-3-octyl-[1,2,4]oxadiazole 

Relevant articles and documents

Design, synthesis and antiparasitic evaluation of click phospholipids

A library of seventeen novel ether phospholipid analogues, containing 5-membered heterocyclic rings (1,2,3-triazolyl, isoxazolyl, 1,3,4-oxadiazolyl and 1,2,4-oxadiazolyl) in the lipid portion were designed and synthesized aiming to identify optimised miltefosine analogues. The compounds were evaluated for their in vitro antiparasitic activity against Leishmania infantum and Leishmania donovani intracellular amastigotes, against Trypanosoma brucei brucei and against different developmental stages of Trypanosoma cruzi. The nature of the substituents of the heterocyclic ring (tail) and the oligomethylene spacer between the head group and the heterocyclic ring was found to affect the activity and toxicity of these compounds leading to a significantly improved understanding of their structure–activity relationships. The early ADMET profile of the new derivatives did not reveal major liabilities for the potent compounds. The 1,2,3-triazole derivative 27 substituted by a decyl tail, an undecyl spacer and a choline head group exhibited broad spectrum antiparasitic activity. It possessed low micromolar activity against the intracellular amastigotes of two L. infantum strains and T. cruzi Y strain epimastigotes, intracellular amastigotes and trypomastigotes, while its cytotoxicity concentration (CC50) against THP-1 macrophages ranged between 50 and 100 μM. Altogether, our work paves the way for the development of improved ether phospholipid derivatives to control neglected tropical diseases.

CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES

The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: (I) wherein, RA1, RA2, RC and RD are as defined herein.

LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS

The invention relates to inhibitors of sphingosine kinase enzymatic activity, compounds and pharmaceutical compositions that inhibit sphingosine kinase 1 and sphingosine kinase 2 (SphK1 and SphK2) enzymes and further relates to methods of treating diseases and disorders mediated by sphingosine 1 phosphate activity, comprising administering an effective amount of sphingosine kinase inhibitors.